Clinical trials can assist you in getting the right treatment for your condition. Before you consider it, here's what you should know.

Enrolment in this trial is expected to continue through the first quarter of 2025. Satellos is on track to submit a Phase II ...

Neumora Therapeutics Inc. concealed critical issues with its flagship clinical depression drug’s Phase 2 trial, contributing ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...

Pliant Therapeutics shares fell sharply in pre-market trading Monday after it said it would pause its pulmonary fibrosis drug following a review by independent monitors. Shares traded 55% lower ahead ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Regeneron has reported positive outcomes from the Phase III trial of Eylea HD in treating individuals with macular oedema ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the ...